Travel Vaccines Market Drivers and Opportunities [2021-2031]
The travel vaccines market size is projected to reach US$ 9.2 billion by 2031 from US$ 4.2 billion in 2023. The market is expected to register a CAGR of 8.7% during 2023–2031. Digitalization for travel vaccines are likely to remain key trends in the market.
Travel Vaccines Market Analysis
Vaccination drives or immunization programs will provide lucrative opportunity for the market growth for travel vaccines in the coming years. Most of the countries have mandated vaccination against several infectious diseases. However, there is a lack of awareness about vaccination in most of the low and middle–income countries. Therefore, several developing countries conduct awareness campaigns for vaccination drives. The United Nations Children's Fund (UNICEF) is one such example that have established a vaccine project to curb rotavirus, pneumococcal conjugate, and human papilloma virus (HPV) in the countries such as Samoa, Tonga, Tuvalu, and Vanuatu. The project is funded by the Asian Development Bank (ADB). ADB deployed US$ 29.7 million for system strengthening the coverage of new vaccines in the Pacific project. The project health ministries immunized 90,700 children against pneumonia, nearly 71,600 children against rotavirus, and 84,200 adolescent girls against HPV infections for the developing countries. Such aforementioned factors act as an influential factor responsible to account considerable market growth during 2021-2031. Digitalization for travel vaccines are likely to remain key trends in the market.
Travel Vaccines Market Overview
Growing incidence of infectious diseases drives the market growth. For example, COVID–19 pandemic has become a threat to public health. According to World Health Organuzation (WHO) report, over 1.53 million people were affected due to pandemic and nearly 3.2 million deaths were registered till May 1, 2021. Several emergency actions were initiated during the pandemic; among which, the COVAX initiative was aggressively enacted. Governments in every region have mandated vaccines for people traveling within and outside countries. The COVID-19 pandemic has contributed a lot to travel vaccines, and it is promoting the growth of the market.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Travel Vaccines Market: Strategic Insights
Travel Vaccines Market
-
CAGR (2023 - 2031)
8.7%
-
Market Size 2023
US$ 4.2 Billion
-
Market Size 2031
US$ 9.2 Billion
Market Dynamics
GROWTH DRIVERS
- Growing incidence of infectious diseases drives the market growth
- Rising International Travel Accelerates Demand for Travel Vaccines which is expected to Favor the Market Growth
FUTURE TRENDS
- Digitalization for travel vaccines are likely to remain key trends in the market.
OPPORTUNITIES
- Rising investment in Research & Development (R&D)for Travel Vaccine to Provide Lucrative Market Opportunities
Key Players
- GSK
- Merck & Co., Inc
- Sanofi
- Novartis
- Pfizer
- Dynavax Technologies
- Emergent Biosolutions Inc.
- Abbott
- Bharat Biotech
- Valneva
Regional Overview
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
Market Segmentation
Product
- Hepatitis A
- Hepatitis B
- Meningococcal Vaccines
- DPT
- Yellow Fever
- Typhoid
- Japanese Encephalitis
- Measles
- Mumps
- Rubella
Application
- Domestic Travel and Outbound Travel
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Travel Vaccines Market: Strategic Insights
-
CAGR (2023 - 2031)8.7% -
Market Size 2023
US$ 4.2 Billion -
Market Size 2031
US$ 9.2 Billion
Market Dynamics
- Growing incidence of infectious diseases drives the market growth
- Rising International Travel Accelerates Demand for Travel Vaccines which is expected to Favor the Market Growth
- Digitalization for travel vaccines are likely to remain key trends in the market.
- Rising investment in Research & Development (R&D)for Travel Vaccine to Provide Lucrative Market Opportunities
Key Players
- GSK
- Merck & Co., Inc
- Sanofi
- Novartis
- Pfizer
- Dynavax Technologies
- Emergent Biosolutions Inc.
- Abbott
- Bharat Biotech
- Valneva
Regional Overview
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
Market Segmentation
- Hepatitis A
- Hepatitis B
- Meningococcal Vaccines
- DPT
- Yellow Fever
- Typhoid
- Japanese Encephalitis
- Measles
- Mumps
- Rubella
- Domestic Travel and Outbound Travel
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Travel Vaccines Market Drivers and Opportunities
Rising International Travel Accelerates Demand for Travel Vaccines to Favor Market
International travellers increase the chance of spreading rare diseases. Therefore, vaccination before travel is imperative to ensure global public health and help travelers stay healthy during and after their travels. The immunizations recommended for travelers vary based on the certain factors. The factors involved the traveler's age, immunization history, existing medical conditions, destinations, planned activities, duration & nature of travel, and legal requirements for entry into visiting countries. Additionally, infants traveling for international trips should be primarily vaccinated for diphtheria, tetanus, acellular pertussis, inactivated polio, and Haemophilus influenzae type B, with or without hepatitis B (DTaP-IPV-Hib or DTaP-HB-IPV-Hib) vaccine and pneumococcal conjugate vaccine. For example, the first dose of the Measles-Mumps-Rubella (MMR) vaccine should be given at an earlier age than usual for children traveling outside of Canada. Therefore, rising infectious diseases accelerate demand for travel vaccines acting as the major drivers of global travel vaccines market share.
Research & Development (R&D) Activities Will Lucrative Market Opportunity
- In December 2021, Emergent BioSolutions Inc. announced the first participant dosed in its phase 1 study, EBS-UFV-001, evaluating the safety, tolerability, and immunogenicity of the company’s investigational universal influenza vaccine candidate. The current version of the influenza vaccine candidate contains multiple components intended to induce broad and supra-seasonal immunity against influenza A viruses.
- In February 2020, Abbott introduced a new inactivated quadrivalent vaccine for influenza. The new vaccine is the first of its kind sub-unit vaccine delivering protection against four virus strains, in India. It is the only 0.5 ml quadrivalent flu vaccine in India that has been approved for usage in children below 3 years.
Therefore, rising R&D activities is seen to leave a positive impact on the travel vaccines market, as it has an opportunity for development of advanced products.
Travel Vaccines Market Report Segmentation Analysis
Key segments that contributed to the derivation of the travel vaccines market analysis are type, application, and end user.
- Based on product, the travel vaccines market is segmented as Hepatitis A, Hepatitis B, meningococcal vaccines, DPT, Yellow Fever, typhoid, Japanese Encephalitis, Measles, Mumps, and Rubella (MMR), rabies, polio, influenza, varicella & shingles, cholera, and others. The Hepatitis A segment held a largest market share in 2023.
- By application, the market is segmented into domestic travel and outbound travel. The outbound travel segment held the largest share of the market in 2023.
Travel Vaccines Market Share Analysis by Geography
The geographic scope of the travel vaccines market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.
North America has dominated the market. In North America region, the US accounts largest share for travel vaccines market. Presence of top manufacturers in the region and their innovative product offerings are the factors contributing to the dominance of the market. Asia Pacific is anticipated to grow with the highest CAGR in the coming years.
Travel Vaccines Market Report Scope
Report Attribute | Details |
---|---|
Market size in 2023 | US$ 4.2 Billion |
Market Size by 2031 | US$ 9.2 Billion |
Global CAGR (2023 - 2031) | 8.7% |
Historical Data | 2021-2022 |
Forecast period | 2024-2031 |
Segments Covered |
By Product
|
Regions and Countries Covered | North America
|
Market leaders and key company profiles |
|
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Travel Vaccines Market News and Recent Developments
The travel vaccines market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the travel vaccines market are listed below:
- Bavarian Nordic A/S announced partnership with Emergent Biosolutions Inc. for acquiring two marketed travel vaccines "Vivotif" for the prevention of typhoid fever and "Vaxchora" against Cholera as well as Phase 3 vaccine candidate to prevent Chikungunya virus. The acquisition aims not only to expand commercial product portfolio and take a leading position in travel vaccines, but also strengthen company's position in pipeline through promising late-stage vaccines. (Source: Bavarian Nordic A/S, Website, February 2023).
Travel Vaccines Market Report Coverage and Deliverables
The “Travel Vaccines Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:
- Travel vaccines market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
- Travel vaccines market trends as well as market dynamics such as drivers, restraints, and key opportunities
- Detailed PEST/Porter’s Five Forces and SWOT analysis
- Travel vaccines market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
- Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the travel vaccines market
- Detailed company profiles
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Product and Application
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
Frequently Asked Questions
North America region dominated the travel vaccines market in 2023.
Rising international travel accelerate demand for travel vaccines is one of the most influential factors responsible for market growth.
Digitalization for travel vaccines to remain as a key trend for travel vaccines market.
GSK, Merck & Co., Inc., Sanofi, Novartis, Pfizer, Dynavax Technologies, Emergent Biosolutions Inc., Abbott, Bharat Biotech, and Valneva are the key players in the travel vaccines market.
The estimated value of travel vaccines market accounted US$ 9.2 billion in 2031.
The CAGR for travel vaccines accounted 8.7% during 2023-2031.